Magnesium for Muscle Function

Table of Contents

1. Magnesium as the Endogenous Calcium Antagonist
2. The Muscle Relaxation Phase — SERCA and Beyond
3. The Neuromuscular Junction
4. Nocturnal Leg Cramps
5. Restless Legs Syndrome and Periodic Limb Movements
6. Eyelid Twitches (Myokymia) and Fasciculations
7. Exercise-Induced Muscle Cramps in Athletes
8. Smooth Muscle — Bronchospasm, Bowel, Vasospasm
9. Choosing the Form: Glycinate vs Malate vs Threonate vs Taurate
10. Dosing, Timing, and Repletion Timelines
11. Why Serum Magnesium Misses Muscle-Cell Deficiency
12. Cautions and Drug Interactions
13. Key Research Papers
14. Connections
15. Featured Videos

Magnesium as the Endogenous Calcium Antagonist

Calcium and magnesium are chemically similar divalent cations — both carry a +2 charge, both have comparable ionic radii, and both interact with the same families of binding proteins, ion channels, and enzymes. The biological consequence is that they compete for nearly every site where the other binds. Where calcium triggers an event, magnesium tends to dampen or reverse it. At the cardiomyocyte, this dynamic governs heart rhythm. At the vascular smooth muscle cell, it governs blood pressure. At the skeletal muscle fiber, it governs contraction and relaxation.

The classical sliding-filament model of muscle contraction makes the antagonism explicit:

1. An action potential arrives at the neuromuscular junction.
2. Calcium is released from the sarcoplasmic reticulum into the cytosol.
3. Calcium binds to troponin C on the thin filament, causing tropomyosin to move out of the way and exposing the myosin-binding sites on actin.
4. Myosin heads bind actin, undergo the power stroke, and the sarcomere shortens.
5. To relax, calcium must be pumped back into the sarcoplasmic reticulum by the SERCA pump (sarcoplasmic/endoplasmic reticulum Ca-ATPase), which is fueled by Mg-ATP.

Magnesium intervenes at multiple steps. It competes with calcium for the troponin C binding site (so adequate magnesium raises the calcium threshold required for contraction, preventing hair-trigger firing). It is the obligate cofactor for the SERCA pump that ends the contraction. It stabilizes the resting membrane potential by setting the threshold for sodium and calcium channel activation. The net effect is that magnesium tonically opposes contraction and supports relaxation.

When magnesium falls, this opposition weakens. The contraction threshold drops, so muscles fire on smaller stimuli (the basis of fasciculations and twitches). The SERCA pump runs slower (because Mg-ATP is limited), so calcium lingers in the cytosol longer than it should, prolonging contraction. And the resting potential becomes less stable, so spontaneous depolarizations occur (the basis of cramps and ectopic contractions). This is why every clinical syndrome of muscle hyperactivity — cramps, twitches, spasms, tetany, restless legs — is a reason clinicians look at magnesium status.

Back to Table of Contents

The Muscle Relaxation Phase — SERCA and Beyond

Of the two halves of the contraction-relaxation cycle, the relaxation half is the one that fails first in magnesium deficiency, and it is the half clinicians and patients underappreciate. Most popular education frames muscle as "contracting" — lifting, gripping, propelling — but a healthy muscle spends most of its time relaxing, and the active machinery that produces relaxation is more biochemically demanding than the machinery that produces contraction.

• SERCA pump kinetics — SERCA is an adenosine triphosphate-dependent calcium pump that moves two calcium ions back into the sarcoplasmic reticulum per adenosine triphosphate hydrolyzed. SERCA accounts for a striking fraction of resting muscle's adenosine triphosphate turnover — estimates range from 15% to 50% depending on muscle type and contraction frequency. Because adenosine triphosphate must be magnesium-complexed to be biologically active, magnesium availability directly sets the speed of the relaxation phase.
• Plasma membrane calcium ATPase (PMCA) — A second pump in the muscle fiber's plasma membrane extrudes calcium from the cell entirely. Also Mg-ATP-dependent. When magnesium is low, the cell's ability to clear cytosolic calcium back to baseline is compromised, and a low-grade tonic contraction develops — the muscle feels "tight."
• Sodium-calcium exchanger (NCX) — A third route by which calcium leaves the cell, indirectly powered by the Na/K-ATPase, which is itself magnesium-dependent. The whole calcium-extrusion system is, in one way or another, magnesium-gated.
• Cross-bridge detachment — Even after calcium is removed from troponin C, the myosin heads must let go of actin. This detachment requires adenosine triphosphate binding — the famous "rigor mortis" of cadaver muscle is the failure of adenosine triphosphate-mediated cross-bridge release. Magnesium deficiency does not produce rigor, but it does slow the release kinetics, contributing to the feeling of tight or stiff muscle.

The clinical implication is that magnesium deficiency is fundamentally a relaxation defect, not a contraction defect. The complaints map accordingly — cramps (failed relaxation after voluntary contraction), restless legs (failed relaxation in supposedly resting muscle), twitches (spontaneous mini-contractions on a destabilized membrane), and the diffuse "tight muscles" complaint that drives so many massage and stretching visits.

Back to Table of Contents

The Neuromuscular Junction

The neuromuscular junction (NMJ) is the synapse between a motor neuron and a skeletal muscle fiber. The presynaptic terminal of the motor neuron releases acetylcholine in response to a calcium influx; acetylcholine then crosses the synaptic cleft and binds nicotinic receptors on the muscle endplate, triggering depolarization and contraction. Magnesium is a powerful presynaptic modulator at the NMJ.

• Presynaptic calcium channel competition — The calcium channels at the motor nerve terminal that trigger acetylcholine release are competitively inhibited by extracellular magnesium. High magnesium reduces acetylcholine release, low magnesium increases it. This is the classical pharmacology that makes intravenous (IV) magnesium sulfate a respiratory depressant at toxic doses and a tocolytic (uterine muscle relaxant) at therapeutic doses in obstetrics.
• Why deficiency triggers fasciculations — When magnesium is low, the presynaptic terminal becomes hyperexcitable. Small subthreshold stimuli release transmitter that would otherwise be ignored, producing the random twitches (fasciculations) that patients commonly describe as "muscles popping" or "worms under the skin."
• Postsynaptic membrane stabilization — Magnesium also stabilizes the postsynaptic endplate by setting the threshold for sodium channel activation. A low-magnesium endplate fires on smaller-than-normal depolarizations.
• Magnesium and neuromuscular blockers — Anesthesiologists know that magnesium potentiates non-depolarizing neuromuscular blockers (rocuronium, vecuronium, atracurium). The same principle that makes hypermagnesemia produce respiratory depression makes intravenous magnesium a useful adjunct to reduce neuromuscular blocker dose — and the reason magnesium supplementation matters to the anesthesia team before surgery.

Back to Table of Contents

Nocturnal Leg Cramps

Nocturnal leg cramps — the sudden, painful, involuntary calf or foot contraction that wakes people from sleep — affect an estimated 30-50% of adults over age 60 and a substantial fraction of pregnant women, particularly in the third trimester. The mechanism is exactly the magnesium-deficient SERCA-failure picture described above — the cytosolic calcium fails to clear after a small spontaneous depolarization, and the muscle locks into a sustained tetanic contraction until the cytosol can finally be cleared (often by stretching, which mechanically displaces the calcium-bound troponin).

• Magnesium for cramp prevention — The 2012 Cochrane review (Garrison and colleagues) concluded that magnesium is unlikely to give clinically meaningful cramp prevention to older adults with ordinary (idiopathic) cramps; for pregnancy-related cramps it called the evidence conflicting — of two placebo-controlled pregnancy trials, one found no benefit and the other found benefit. A 2014 meta-analysis (Sebo and colleagues; 7 randomized controlled trials, RCTs, with 361 people, 3 of them in pregnant women only) concluded that magnesium does not appear effective for nocturnal leg cramps in the general population but may have a small effect in pregnant women, and rated the strength of this evidence as weak.
• Why the older general-population data is mixed — Most negative trials enrolled subjects without documented magnesium deficiency. Cramp etiology is heterogeneous: dehydration, electrolyte imbalance, statin use, peripheral artery disease, and motor neuron disease all produce cramps that magnesium won't fix. Supporters of magnesium argue that people with documented deficiency would respond better.
• Quinine alternatives — Quinine sulfate was the historical first-line drug for nocturnal cramps. In July 2010 the U.S. Food and Drug Administration (FDA) stated that quinine sulfate should not be used for night-time leg cramps, citing serious and life-threatening blood reactions (bleeding from very low platelets, and hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura), and required a medication guide; the drug is approved only for uncomplicated Plasmodium falciparum malaria. Magnesium is widely used over the counter as an alternative.
• Doses commonly used — Practitioners commonly use 200-400 mg of elemental magnesium (glycinate, citrate, or malate) at bedtime for 4-8 weeks, with reassessment. The pregnancy trials used about 200-360 mg elemental magnesium a day; in the trials reviewed, gastrointestinal side effects were slightly more common than with placebo (Sebo 2014), and withdrawals because of side effects did not differ significantly from placebo (Cochrane 2012).

Back to Table of Contents

Restless Legs Syndrome and Periodic Limb Movements

Restless legs syndrome (RLS) is a sensorimotor disorder characterized by an urge to move the legs (often accompanied by uncomfortable sensations) that is worse at rest and at night, and relieved by movement. Periodic limb movements of sleep (PLMS) are the related phenomenon of involuntary leg jerks during sleep that often fragment sleep architecture. The two conditions overlap heavily and respond to similar interventions.

• The Hornyak 1998 trial — The seminal trial of magnesium for RLS/PLMS was an open-label study by Hornyak and colleagues in Sleep, treating 10 patients with mild-to-moderate RLS/PLMS-related insomnia with 12.4 mmol (~300 mg elemental) of oral magnesium in the evening for 4-6 weeks. PLMS-related arousals fell from 17/hour to 7/hour, sleep efficiency improved from 75% to 85%, and 7 of the 10 patients rated their sleep and/or RLS symptoms as improved.
• The iron-magnesium-dopamine axis — RLS pathophysiology centers on brain iron deficiency (specifically in the substantia nigra) and impaired dopaminergic signaling. Magnesium is not a primary driver but supports the dopamine synthesis pathway and stabilizes the dorsal pons sensory circuits implicated in the leg sensations. A complete RLS workup includes ferritin (target >75 ng/mL), iron, transferrin saturation, magnesium, and a review of medications that exacerbate RLS (selective serotonin reuptake inhibitors (SSRIs), dopamine antagonists, antihistamines).
• Doses used for RLS — 300-500 mg elemental magnesium (glycinate or chelate forms, which practitioners favour for tolerability) 1-2 hours before bedtime, alongside adequate iron and a careful medication review. RLS responsive to magnesium tends to be the mild-to-moderate, non-familial, mid-life-onset subtype; severe early-onset familial RLS often requires dopaminergic therapy.
• PLMS in dialysis patients — chronic kidney disease (CKD) patients are at elevated RLS/PLMS risk and at elevated risk for both iron and magnesium dysregulation. In chronic kidney disease, impaired excretion means magnesium supplements can cause hypermagnesemia, so magnesium status matters in both directions.

Back to Table of Contents

Eyelid Twitches (Myokymia) and Fasciculations

The benign eyelid twitch — technically called orbicularis oculi myokymia — is one of the most common neuromuscular complaints in primary care and one of the most frequently magnesium-responsive. It is a sustained, irritating fluttering of the lower (occasionally upper) eyelid that can persist for hours, days, or weeks. The classical associations are caffeine excess, sleep deprivation, stress, and magnesium deficiency — often all four at once in a single patient.

• Mechanism — Myokymia is a low-grade fasciculation arising from spontaneous depolarization of motor neurons supplying the orbicularis oculi. Magnesium deficiency lowers the firing threshold; caffeine adenosine antagonism raises sympathetic tone; sleep deprivation depletes intracellular magnesium; stress consumes magnesium through hypothalamic-pituitary-adrenal-axis activation. The combination produces a perfectly tuned condition for spontaneous muscle firing.
• Common self-care approach — The classical self-care approach is cutting caffeine to under 200 mg/day for two weeks, sleeping at least 7 hours a night, and taking 200-400 mg magnesium glycinate daily; people commonly report the twitch settling within 1-2 weeks, and some notice improvement within 24-48 hours of the first dose.
• When doctors investigate further — Twitching that spreads beyond the eyelid, persists more than a month, or comes with weakness is the pattern that leads to neurological evaluation for hemifacial spasm, blepharospasm, or rarely a motor neuron disorder. Pure orbicularis myokymia without spread is considered benign.
• Generalized fasciculations — Random "popping" sensations in the calves, thighs, or upper arms, particularly when at rest, are another classical magnesium-deficiency symptom. The pattern is benign when bilateral, intermittent, not accompanied by weakness, and resolves with magnesium repletion. Persistent one-sided fasciculations with weakness are the pattern that leads to an amyotrophic lateral sclerosis (ALS) workup; magnesium deficiency presents diffusely and resolves with treatment.

Back to Table of Contents

Exercise-Induced Muscle Cramps in Athletes

Exercise-associated muscle cramps (EAMCs) are the abrupt, painful, often-debilitating cramps that strike endurance athletes mid-event — the marathoner who locks up at mile 22, the cyclist who cramps a calf on a long climb, the triathlete who can't finish the swim. The classical explanation was electrolyte and fluid loss from sweat, with sodium and magnesium as the leading suspects. Modern research has complicated this picture, identifying a neuromuscular fatigue mechanism that runs in parallel.

• The electrolyte mechanism — Sustained heavy sweat losses (1-2 liters per hour during intense endurance work) deplete sodium and chloride and, secondarily, magnesium. Total-body magnesium falls slowly because most magnesium is intracellular, but the rate of decline accelerates in athletes who don't replete daily. Athletes with chronic low intake can run a low-grade deficit through a season that finally manifests as race-day cramps.
• The neuromuscular fatigue mechanism — Studies by Schwellnus and colleagues have shown that EAMCs can occur in well-hydrated, electrolyte-replete athletes — suggesting that altered neuromuscular control under fatigue plays a primary role. The current model is that fatigued motor neurons lose inhibitory input from Golgi tendon organs while gaining excitatory input from muscle spindles, producing the runaway firing that causes a cramp.
• The pickle-juice phenomenon — In a 2010 trial by Miller and colleagues in dehydrated (hypohydrated) men, electrically induced cramps in a small foot muscle lasted 84.6 seconds after drinking 1 mL/kg of pickle juice (a strong acidic, sodium-rich, vinegar-based brine) versus 133.7 seconds after deionized water — about 49 seconds shorter. The mechanism appears to be neural, not metabolic — the acidic taste triggers an oropharyngeal reflex that inhibits motor neuron firing. The pickle-juice effect doesn't replace electrolyte management but illustrates that the neural-control side is real.
• Approaches used by athletes — Daily oral magnesium (200-400 mg elemental, glycinate or malate) through training season; race-day attention to sodium (oral rehydration salts, electrolyte tablets); during multi-hour events, periodic intake of carbohydrate + electrolyte solutions; immediate stretching of the cramping muscle when one strikes; and for some athletes, pickle juice or vinegar shots as an acute remedy. Magnesium malate is particularly favored by athletes because malic acid is a Krebs cycle intermediate that may support muscle energy metabolism during heavy training.

Back to Table of Contents

Smooth Muscle — Bronchospasm, Bowel, Vasospasm

Magnesium's muscle-relaxing effects extend beyond skeletal muscle to smooth muscle throughout the body, with clinically relevant applications in pulmonology, gastroenterology, obstetrics, and cardiology.

• Intravenous magnesium for severe asthma — Magnesium sulfate (typically 2 g intravenous over 20 minutes) is established adjunct therapy for severe acute asthma exacerbations unresponsive to first-line bronchodilators. The mechanism is direct relaxation of bronchial smooth muscle via calcium channel blockade. NICE and GINA guidelines support this use in ED management of severe asthma.
• Magnesium in chronic constipation — Magnesium citrate and magnesium hydroxide (milk of magnesia) are osmotic laxatives that work partly through luminal magnesium drawing water into the bowel and partly through smooth muscle relaxation and cholecystokinin release. For functional constipation, magnesium citrate 200-400 mg/day is a first-line option.
• Tocolysis (uterine relaxation) — intravenous magnesium sulfate was historically used to suppress preterm labor, exploiting smooth muscle relaxation in the myometrium. Modern obstetric practice has largely replaced magnesium tocolysis with calcium channel blockers (nifedipine), but intravenous magnesium remains a cornerstone of preeclampsia management — for seizure prevention rather than primary tocolysis.
• Coronary vasospasm — Prinzmetal's angina (variant angina) involves intermittent spasm of coronary arteries. Magnesium has been used as adjunct therapy in case series, exploiting smooth muscle calcium antagonism in arterial walls. The mainstay treatments are nitrates and calcium channel blockers, with magnesium status often assessed and corrected alongside.
• Esophageal spasm — Diffuse esophageal spasm and "nutcracker esophagus" can respond to magnesium supplementation, again through smooth muscle calcium antagonism. The evidence is largely anecdotal but mechanistically plausible.

Back to Table of Contents

Choosing the Form: Glycinate vs Malate vs Threonate vs Taurate

The choice of magnesium form matters more for muscle complaints than for many other indications, because the muscle response is dose-dependent and tolerability determines whether the patient sustains a therapeutic dose for the weeks needed to reload muscle stores. The four forms below are the muscle-relevant short list.

Magnesium Glycinate

• Composition — Magnesium chelated with glycine (an inhibitory amino acid that itself supports muscle relaxation and sleep).
• Commonly used for — Nocturnal leg cramps, eyelid twitches, RLS, generalized fasciculations, anxiety-related muscle tension. The glycine adds a calming layer that synergizes with magnesium for nighttime use.
• Bioavailability — Excellent; chelated minerals bypass much of the saturable cation absorption pathway.
• Tolerability — Best of the major forms; minimal gastrointestinal (GI) effect, low laxative tendency. Most reliably tolerated at therapeutic doses.
• Typical dose for muscle — 200-400 mg elemental magnesium at bedtime.
• Deep dive — See Magnesium Glycinate.

Magnesium Malate

• Composition — Magnesium bound to malic acid, a Krebs cycle intermediate involved in cellular adenosine triphosphate production.
• Commonly used for — Athletes, fibromyalgia, chronic fatigue syndrome, exercise-induced cramps, daytime muscle complaints. The malic acid may support muscle energy metabolism, and the form is described as energizing rather than sedating, which is why it is used in the morning or before workouts.
• Bioavailability — Good; comparable to citrate.
• Tolerability — Generally well tolerated; some find it slightly stimulating, hence the daytime preference.
• Typical dose for muscle — 300-500 mg elemental magnesium split AM/lunch.
• Fibromyalgia evidence — A 1995 pilot study (Russell and colleagues, 24 patients) of a tablet combining magnesium (50 mg) with malic acid (200 mg) found no clear treatment effect in its blinded, fixed low-dose phase; pain and tenderness scores fell only in the later 6-month open-label phase with higher doses. The rationale practitioners give is mechanistic (adenosine triphosphate-deficit muscles get a relaxation cofactor plus a Krebs substrate).

Magnesium L-Threonate

• Composition — Magnesium bound to L-threonic acid, a metabolite of vitamin C.
• Commonly used for — Neurologically-mediated muscle complaints (RLS, neuropathic muscle pain, post-stroke spasticity, brain fog accompanying muscle complaints). Threonate is the only form with reproducible blood-brain barrier penetration, raising cerebrospinal fluid magnesium where central nervous system effects matter.
• Bioavailability — Moderate at the muscle (lower elemental magnesium per gram of compound) but unique for central nervous system (CNS) uptake.
• Tolerability — Generally well tolerated; no significant laxative effect.
• Typical dose — 1500-2000 mg of magnesium threonate compound (providing ~144 mg elemental magnesium) in the evening.
• Cost caveat — Significantly more expensive than glycinate or malate, so it is usually kept for indications where central nervous system penetration matters.

Magnesium Taurate

• Composition — Magnesium bound to taurine, a sulfur-containing amino acid with cardiovascular and central nervous system calming effects.
• Commonly used for — Patients with combined muscle + cardiovascular complaints (palpitations, hypertension, exercise intolerance with cramping). Taurine independently supports heart rhythm and muscle membrane stability.
• Bioavailability — Good.
• Typical dose — 200-400 mg elemental magnesium.

Magnesium Citrate (Note)

• Citrate is the cheapest, most widely available, and well-absorbed form, but its laxative effect at therapeutic muscle doses (300-400 mg) often limits use. It works well at lower doses and for patients who also want a mild bowel-stimulating effect, but glycinate or malate is more often used for sustained muscle therapy.

Forms Less Suited to Muscle Use

• Magnesium oxide — Bioavailability around 4%; mostly produces a laxative effect with minimal systemic magnesium loading. Not a first-line muscle therapy despite its low cost and high label content.
• Magnesium aspartate — Some neuroexcitatory concerns at high dose; rarely necessary given better alternatives.

Back to Table of Contents

Dosing, Timing, and Repletion Timelines

• Starting dose — 200 mg elemental magnesium daily, increased to 300-400 mg over 1-2 weeks as tolerated. Splitting into AM + PM doses improves absorption and reduces gastrointestinal effects.
• Loading period — Intracellular magnesium replenishment is slow because magnesium re-equilibration across the cell membrane is constrained by transporters. Practitioners describe 4-8 weeks of consistent intake before peak muscle benefit, so results after 1-2 weeks are not the full picture.
• Pregnancy — 200-360 mg/day in the pregnancy cramp trials.
• Athletes — 300-500 mg/day during heavy training blocks, with attention to total electrolyte status (sodium, potassium, magnesium together).
• Severe RLS/cramps — Up to 600 mg/day under clinical supervision, with parallel iron repletion if ferritin is low.
• Timing — Glycinate at bedtime for sleep-related cramps and RLS; malate in the morning or pre-workout for athletes and daytime muscle complaints; split dosing for either if total daily dose exceeds 300 mg.
• Dietary foundation — Magnesium-rich foods supply magnesium alongside any supplement (pumpkin seeds, spinach, Swiss chard, almonds, black beans, dark chocolate, avocado). Pumpkin seeds at 150 mg per ounce are the standout single food.
• Synergistic cofactors — Vitamin B6 supports cellular magnesium uptake; magnesium works alongside adequate potassium and sodium status (hypokalemia is often magnesium-driven); vitamin D3 (with K2) for muscle and bone integrity; iron (ferritin > 75) for RLS.

Back to Table of Contents

Why Serum Magnesium Misses Muscle-Cell Deficiency

Standard serum magnesium is one of the least sensitive tests in clinical chemistry for the question patients actually want answered. Only about 1% of total-body magnesium is in serum; the rest is in bone (~60%), muscle (~25%), and other soft tissues (~14%). Homeostatic mechanisms vigorously defend serum magnesium — the kidney aggressively conserves it, parathyroid hormone and FGF23 modulate intestinal absorption — so a person can be substantially intracellularly deficient with serum magnesium still in the "normal" reference range.

• Why this matters for muscle — Muscle fibers are the second-largest magnesium reservoir in the body, and the contraction-relaxation symptoms develop when intramuscular magnesium falls, not when serum falls. A patient with normal serum magnesium and clinical cramps/twitches/RLS is exactly the patient whose muscle compartment is depleted.
• Better tests
  • RBC magnesium — Red blood cell magnesium reflects intracellular magnesium and is the most accessible non-serum test. Practitioners aim for the upper half of the reference range.
  • Ionized magnesium — Measures the biologically active free ionic fraction. Less commonly available.
  • 24-hour urinary magnesium — In conjunction with a magnesium loading test (oral or intravenous bolus followed by 24-hour urine collection), this measures the body's capacity to retain magnesium — a low excretion fraction after a load indicates whole-body deficiency.
  • Magnesium tolerance test — The research gold standard; rarely done clinically.
• The empiric trial — In primary care practice, the approach is often empiric: when someone has classical magnesium-responsive symptoms (cramps, twitches, RLS, anxiety-with-tight-muscles) and no contraindications (chronic kidney disease, heart block), practitioners commonly use a 4-8 week trial of 300-400 mg elemental magnesium and treat the symptomatic response as evidence of deficiency; the trial is cheap and low-risk for people without those contraindications.

See the Magnesium Test page for more detail on testing options and interpretation.

Back to Table of Contents

Cautions and Drug Interactions

• Chronic kidney disease — Impaired magnesium excretion can produce hypermagnesemia (nausea, hypotension, bradycardia, respiratory depression in severe cases). This is the main hazard of magnesium supplements in kidney disease.
• Heart block — Magnesium slows AV conduction, so high doses are a concern in second- or third-degree AV block.
• Pre-surgical disclosure — Magnesium potentiates non-depolarizing neuromuscular blockers, so magnesium supplementation is relevant information for the anesthesia team before surgery.
• Bisphosphonates and quinolones — Magnesium chelates these drugs; the usual practice is to separate doses by 2-4 hours (4 hours for levothyroxine).
• Diuretics — Loop and thiazide diuretics waste magnesium; people on long-term diuretic therapy often run low, and serum magnesium is monitored.
• Diarrhea — The dose-limiting side effect; chelated forms (glycinate, malate, threonate) cause loose stools less often than citrate or oxide.
• Anticonvulsants — Phenytoin and phenobarbital can deplete magnesium with chronic use, so magnesium is monitored in long-term use.

Note: This content is informational. Persistent muscle symptoms, unexplained weakness, or symptoms accompanied by weight loss, fever, or neurological changes point to causes beyond magnesium. In kidney disease, impaired excretion can raise blood magnesium to harmful levels (nausea, low blood pressure, slow heart rate, and in severe cases depressed breathing); magnesium also slows heart conduction in heart block and adds to the effect of the muscle relaxants used in anesthesia.

Back to Table of Contents

Key Research Papers

1. Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D (1998). Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep. — PubMed PMID: 9703590
2. Sebo P, Cerutti B, Haller DM (2014). Effect of magnesium therapy on nocturnal leg cramps: a systematic review of randomized controlled trials with meta-analysis using simulations. Family Practice. — PubMed PMID: 24280947
3. Garrison SR, Allan GM, Sekhon RK, Musini VM, Khan KM (2012). Magnesium for skeletal muscle cramps. Cochrane Database Syst Rev. — PubMed PMID: 22972143
4. Dahle LO et al. (1995). The effect of oral magnesium substitution on pregnancy-induced leg cramps. Am J Obstet Gynecol. — PubMed PMID: 7631676
5. Miller KC, Mack GW, Knight KL, et al. (2010). Reflex inhibition of electrically induced muscle cramps in hypohydrated humans. Med Sci Sports Exerc. (pickle juice trial) — PubMed PMID: 19997012
6. Schwellnus MP (2009). Cause of exercise associated muscle cramps (EAMC) — altered neuromuscular control, dehydration or electrolyte depletion? Br J Sports Med. — PubMed PMID: 18981039
7. Russell IJ, Michalek JE, Flechas JD, Abraham GE (1995). Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol. — PubMed PMID: 8587088
8. de Baaij JH, Hoenderop JG, Bindels RJ (2015). Magnesium in man: implications for health and disease. Physiological Reviews. — PubMed PMID: 25540137
9. Lukaski HC (2004). Vitamin and mineral status: effects on physical performance. Nutrition. — PubMed PMID: 15212745
10. Nielsen FH, Lukaski HC (2006). Update on the relationship between magnesium and exercise. Magnesium Research. — PubMed PMID: 17172008
11. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. (2014). Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria — history, rationale, description, and significance. Sleep Med. 15(8):860-73. — PubMed PMID: 25023924

PubMed Topic Searches

1. PubMed: Magnesium and muscle cramps RCTs
2. PubMed: Magnesium and RLS
3. PubMed: Magnesium and fasciculations/myokymia
4. PubMed: IV magnesium for severe asthma
5. PubMed: SERCA and muscle relaxation

Back to Table of Contents

Connections

• All Minerals
• Magnesium: The Mineral That Makes Adenosine Triphosphate Work — interactive animation
• Magnesium Benefits Hub
• Magnesium
• Magnesium for Heart Health
• Magnesium for Sleep
• Magnesium for Migraines
• Magnesium Glycinate
• Calcium
• Calcium and Muscle Function
• Calcium and Muscle Function (Deep Dive) — excitation-contraction coupling, cramps, tetany, and the calcium-magnesium balance for cardiac and skeletal muscle.
• Potassium
• Sodium
• Vitamin B6
• Vitamin D3
• Glycine
• Taurine
• Cramp Prevention
• Stress Management
• Restless Legs Syndrome
• Asthma
• Magnesium Test
• Deficiency
• Toxicity
• History
• Sources

Back to Table of Contents

Featured Videos

×